(VRTX) |
| 0 (0%) 10-10 11:47 |
| Open: | |
| High: | |
| Low: | |
| Volume: | 0 |
| Market Cap: | 0(M) |
| PE Ratio: | 0 |
| Exchange: | |
| Industry: | |
| Sector: |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 493.74 |
| Resistance 1: | 422.73 |
| Pivot price: | 398.08 |
| Support 1: | 392.72 |
| Support 2: | 374.17 |
| 52w High: | |
| 52w Low: |
Financials
| EPS | 14.060 |
| Book Value | 67.010 |
| PEG Ratio | 0.00 |
| Gross Profit | 23.402 |
| Profit Margin (%) | 31.86 |
| Operating Margin (%) | 38.93 |
| Return on Assets (ttm) | 13.1 |
| Return on Equity (ttm) | 22.8 |
Company news
Fri, 10 Oct 2025
Evercore ISI Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Fri, 10 Oct 2025
Optas LLC Lowers Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Fri, 10 Oct 2025
Vontobel Holding Ltd. Decreases Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Wed, 08 Oct 2025
RBC Capital Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Cuts Target Price to $423 - 富途牛牛
Wed, 08 Oct 2025
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know - Yahoo Finance
Wed, 08 Oct 2025
Vertex Pharmaceuticals (VRTX): Buy, Sell, or Hold Post Q2 Earnings? - FinancialContent
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
